Please assess the completion status of the following clinical trial:

Trial Title: A Study of High Dose MHAA4549A in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* Body mass index (BMI) between 18 and 32 kg/m2, inclusive~* Weight 40 - 100 kg~* In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs, and clinical laboratory evaluations~* Willing to use acceptable contraceptive measures as defined by the protocol~* Agreeable to, and deemed able to by the investigator, to comply with the requirements of the study, including the follow-up period~* Willing to abstain from the use of drugs of abuse while enrolled in the study~Exclusion Criteria:~* History or clinically significant manifestations of disorders~* History of acute allergic reaction or drug allergies~* History or presence of an abnormal ECG~* History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit~* History of significant drug abuse within 1 year prior to screening~* Current tobacco smokers~* Positive drug screen at screening or at check-in~* Positive pregnancy test result at screening or Day -1 or breast feeding during the study~* Males who have a pregnant female partner~* Donation of plasma within 7 days prior to study drug administration~* Donation or loss of whole blood~* Receipt of blood products within 2 months before initiation of dosing on Day 1~* History of malignancy within 10 years of screening except completely excised basal cell carcinoma or squamous cell carcinoma of the skin~* History of severe systemic bacterial, fungal, or parasitic infections associated with more than two hospitalizations per year or more than two courses of intravenous (IV) antibiotics within 1 year~* Received oral antibiotics within 4 weeks before initiation of dosing on Day 1, or IV antibiotics within 8 weeks before initiation of dosing~* Hospitalization within 4 weeks before initiation of dosing on Day 1~* Use of any over the counter or prescription medications/products within 7 days prior to Day 1 and unwilling to abstain from the use of such drugs up until at least the Day 29 study visit, unless deemed acceptable by the investigator and Sponsor~* Participation in a clinical trial within 4 weeks~* Received any vaccine within 14 days prior to screening~* Positive blood test for chronic viral infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MHAA4549A higher dose (Type: EXPERIMENTAL): None
- MHAA4549A lower dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).